| Autor: |
Ang JL; Ophthalmology Department, Royal Free London NHS Foundation Trust, London, UK., Ah-Moye S; Ophthalmology Department, Royal Free London NHS Foundation Trust, London, UK., Kim LN; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia., Nguyen V; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia., Hunt A; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia., Barthelmes D; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia.; Department of Ophthalmology, University Hospital Zurich & University of Zurich, Zurich, Switzerland., Gillies MC; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia., Mehta H; Ophthalmology Department, Royal Free London NHS Foundation Trust, London, UK. HM@cantab.net.; Macular Research Group, Save Sight Institute, University of Sydney, Sydney, NSW, Australia. HM@cantab.net. |
| Abstrakt: |
This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24 months. Primary outcome was change in VA (logMAR letters) at 12 months. Study quality was assessed using the quality appraisal checklist for case series developed by Institute of Health Economics. The mean baseline VA for the pooled data was 54.0 (51.5, 56.5) letters and the mean baseline CST was 501.3 (483.5, 519.1) µm. The random-effects estimate for mean (95% CI) change in VA was 14.6 (12.5, 16.7) letters at 12 months (n = 1727). The random-effects estimate for mean (95% CI) change in CST was -181.7 (-230.7, -132.7) µm at 12 months (n = 1325). The quality of studies varied considerably. Ocular and systemic adverse events were discussed in 79% and 42% of treatment arms respectively, with possible under-reporting. Visual and anatomical gains achieved in the real-world for anti-VEGF therapy were not as impressive as seminal RCTs, possibly due to reduced injection frequency in the real world and differences in baseline characteristics. There is an urgent need for consensus on the minimum efficacy, treatment burden and safety data to collect to strengthen the real-world evidence base. |
Full text from SpringerLink